Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Phase 3

Completed

Conditions: Neurodermatitis

Interventions: Drug: Dupilumab SAR231893
Drug: Placebo
Drug: Moisturizers
Drug: Low to medium potent topical corticosteroids
Drug: Topical calcineurin inhibitors

First Posted Date: 2019-12-03

Last Posted Date: 2022-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 151

Registration Number: NCT04183335

Locations: 🇺🇸
Investigational Site Number :8400001, Dublin, Ohio, United States
🇺🇸
Investigational Site Number :8400025, Houston, Texas, United States
🇺🇸
Investigational Site Number :8400011, Gilbert, Arizona, United States

and more 60 locations

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Placebo
Drug: Dupilumab SAR231893
Drug: non sedating H1-antihistamine

First Posted Date: 2019-11-27

Last Posted Date: 2024-12-11

Lead Sponsor: Sanofi

Target Recruit Count: 397

Registration Number: NCT04180488

Locations: 🇺🇸
Allergy & Asthma Specialists, PSC Site Number : 8400020, Owensboro, Kentucky, United States
🇺🇸
Johns Hopkins University (Asthma and Allergy Center) Site Number : 8400016, Baltimore, Maryland, United States
🇺🇸
Allergy and Clinical Immunology Associates Site Number : 8400024, Pittsburgh, Pennsylvania, United States

and more 98 locations

Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: SAR442168

First Posted Date: 2019-11-20

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT04171310

Locations: 🇬🇧
Investigational Site Number 8260001, Nottingham, United Kingdom

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: SAR408701
Drug: Docetaxel

First Posted Date: 2019-11-07

Last Posted Date: 2024-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 389

Registration Number: NCT04154956

Locations: 🇮🇳
Investigational Site Number : 3560011, Trivandrum, India
🇺🇸
National Jewish Health Site Number : 8400033, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists South Division Site Number : 8400020, Fort Myers, Florida, United States

and more 201 locations

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

Phase 4

Withdrawn

Conditions: Fabry Disease

Interventions: Drug: agalsidase beta (GZ419828)
Drug: agalsidase alfa

First Posted Date: 2019-10-30

Last Posted Date: 2023-04-07

Lead Sponsor: Sanofi

Registration Number: NCT04143958

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

Not Applicable

Completed

Conditions: Sphingomyelin Lipidosis

Interventions: Procedure: Investigational Procedures

First Posted Date: 2019-09-27

Last Posted Date: 2023-08-16

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT04106544

Locations: 🇧🇷
Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇷
Investigational Site Number :0320002, Caba, Argentina
🇹🇷
Investigational Site Number :7920001, Izmir, Turkey

and more 25 locations

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Phase 4

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin glargine, 300 U/ml
Drug: Insulin degludec, 100U/ml

First Posted Date: 2019-08-30

Last Posted Date: 2022-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 343

Registration Number: NCT04075513

Locations: 🇬🇧
Investigational site United Kingdom, United Kingdom, United Kingdom
🇭🇺
Investigational site Hungary, Hungary, Hungary
🇺🇸
United States, Dallas, Texas, United States

and more 4 locations

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Phase 2

Completed

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Drug: Caplacizumab (ALX-0081)
Drug: Plasma exchange (PE)
Drug: Corticosteroid treatment (Methylprednisolone or prednisolone)
Drug: Immunosuppressive treatment (eg, rituximab)

First Posted Date: 2019-08-29

Last Posted Date: 2023-02-01

Lead Sponsor: Sanofi

Target Recruit Count: 21

Registration Number: NCT04074187

Locations: 🇯🇵
Investigational Site Number 3920009, Iruma-Gun, Japan
🇯🇵
Investigational Site Number 3920007, Kashihara-Shi, Japan
🇯🇵
Investigational Site Number 3920003, Kurashiki-Shi, Japan

and more 9 locations

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer Metastatic

Interventions: Drug: Amcenestrant
Drug: Fulvestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen

First Posted Date: 2019-08-16

Last Posted Date: 2025-01-27

Lead Sponsor: Sanofi

Target Recruit Count: 367

Registration Number: NCT04059484

Locations: 🇺🇦
Investigational Site Number : 8040001, Kryvyi Rih, Ukraine
🇬🇷
Investigational Site Number : 3000004, Thessaloniki, Greece
🇧🇷
Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil

and more 106 locations

Acne Vulgaris Related Microbiology and Serology

Completed

Conditions: Acne Vulgaris

Interventions: Diagnostic Test: Study of humoral immunity

First Posted Date: 2019-08-14

Last Posted Date: 2021-01-06

Lead Sponsor: Sanofi

Target Recruit Count: 120

Registration Number: NCT04056598

Locations: 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States

Home Terms & Conditions Privacy Policy